Sunday 18 October 2026
Export VNDA’s income statement to Excel — free account
Vanda Pharmaceuticals Inc.
VNDA Healthcare Biotechnology
Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024. In the quarter to June 2026, revenue fell 3.92%, EPS fell 126.1%, free cash flow fell 101.0% and total debt rose 2.98%, each against the same quarter a year earlier.
4.03
0.21
−4.95%
Follow VNDA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.71 | 1.89 | 2.41 | 1.39 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.86) | (8.18) | (17.67) | (9.32) | |
P/B ratio |
1.67 | 1.46 | 1.59 | 0.63 | |
Price to Tangible BV |
3.44 | 2.48 | 2.47 | 0.83 | |
EV/Sales |
0.94 | 0.98 | 1.20 | 0.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.42) | (1.68) | (2.38) | (0.05) | |
EV/FCF |
(1.32) | (1.55) | (2.35) | (0.05) | |
Quick Ratio |
1.40 | 1.91 | 2.19 | 2.92 | |
Current Ratio |
1.61 | 2.16 | 2.39 | 3.12 | |
Net Debt/EBITDA |
2.77 | 4.24 | 7.48 | 9.25 | |
Debt/Assets |
0.77% | 0.87% | 0.83% | 0.47% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.42 | 0.41 | 0.38 | 0.34 | |
Operating CF/Net income |
0.50 | 1.03 | 0.21 | 1.40 | |
Capex/Depreciation |
(0.05) | (3.01) | (0.02) | 1.02 | |
Research and Development Expense of Revenue |
73.13% | 54.98% | 50.70% | 40.11% | |
Selling, General and Administrative Expense of Revenue |
142.17% | 132.18% | 110.07% | 107.14% | |
Intangible Assets out of Total Assets |
0.27 | 0.27 | 0.24 | 0.18 | |
Share Based Compensation of Revenue |
4.17% | 4.96% | 3.99% | 3.75% | |
Graham Net Nets |
0.20 | 0.34 | 0.36 | 0.79 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(75.65%) | (58.61%) | (42.29%) | (28.46%) | |
Free Cash Flow Yield |
(41.51%) | (33.42%) | (21.25%) | (28.13%) | |
Revenue per Share |
0.84 | 0.87 | 0.97 | 0.95 | |
Operating CF per Share |
(0.52) | (0.84) | (0.50) | (0.54) | |
Capex per Share |
0.00 | (0.17) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.52) | (1.02) | (0.50) | (0.54) | |
Cash per Share |
2.82 | 3.40 | 4.48 | 4.97 | |
Shareholders Equity per Share |
3.66 | 4.72 | 5.55 | 7.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.66 | 4.72 | 5.55 | 7.89 | |
Free Cash Flow |
(31.26) | (60.44) | (29.52) | (31.79) | |
Working Capital |
100.46 | 157.59 | 202.10 | 249.63 | |
Capital Expenditures |
(0.19) | (10.22) | (0.10) | (0.16) | |
Net Current Asset Value |
72.20 | 140.41 | 185.50 | 232.36 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.20 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
52.34 | 50.74 | 50.84 | 46.65 | |
Average Payables |
63.56 | 52.95 | 53.69 | 43.46 | |
Average Inventory |
1.92 | 1.81 | 1.79 | 1.83 | |
Average Assets |
518.61 | 532.73 | 572.58 | 623.13 | |
Average Common Equity |
353.26 | 396.09 | 432.87 | 503.61 |
Columns are period end dates